Vesicor Therapeutics, Inc. entered into a business combination agreement to acquire Altitude Acquisition Corp. (NasdaqCM:ALTU) for $71.96 million in a reverse merger transaction on February 29, 2024. Each share of common stock of the Vesicor, par value $0.001 per share (? Vesicor Common Stock ?) held by a Vesicor securityholder immediately prior to the Effective Time (not including dissenting shares) shall be automatically cancelled and converted into the right to receive a pro rata portion of a number of shares of common stock of New Vesicor, par value $0.001 per share (? New Vesicor Common Stock ?) equal to (i)(a) $70,000,000 plus (b) Closing Cash (as defined in the Business Combination Agreement) minus (c) Closing Indebtedness (as defined in the Business Combination Agreement), (ii) divided by $10.00. Each of Vesicor?s warrants that are outstanding and unexercised prior to the Merger, whether or not then exercisable, will be assumed by New Vesicor and will be converted into a warrant to acquire shares of New Vesicor Common Stock and will be subject to the same terms and conditions that applied to the Vesicor warrant immediately prior to the Merger. The Business Combination Agreement provides, among other things, that on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into Vesicor (the ? Merger ?), with Vesicor surviving as a wholly-owned subsidiary of the Company (the ? Surviving Corporation ?). The initial board of directors of New Vesicor following the Closing will consist of five members, of which one will be designated by Sponsor and the remaining four will be designated by Vesicor, with at least three of such designees qualifying as independent directors. Executive management of Vesicor will become the executive management of New Vesicor following the Closing. Upon the closing of the Merger (the ? Closing ?), it is anticipated that the Company will change its name to ?Vesicor Therapeutics, Inc.? and is referred to herein as ?New Vesicor? as of the time following such change of name.

The transaction is subject to the satisfaction or waiver of certain customary closing conditions of the respective parties, including, without limitation: (i) the approval and adoption of the Business Combination Agreement and transactions contemplated thereby by requisite vote of the Company?s stockholders (the ? Company Stockholder Approval ?) and Vesicor?s stockholders (the ? Vesicor Stockholder Approval ?); (ii) the receipt of consents or approvals from the applicable governmental, regulatory or administrative authorities and each applicable waiting period or consent or approval under the HSR Act shall have expired, been terminated or obtained; (iii) there has not been any legal action, suit, claim or similar hearing or proceeding brought by any governmental body, agency, authority, court, arbitrator, or any public, private or industry regulatory authority, whether international, national, foreign, Federal, state, or local. to enjoin or otherwise restrict the consummation of the transactions; (iv) Vesicor shall have performed or complied with, in all material respects, all of its obligations required to be performed or complied with at or prior to the Closing Date; (v) the Company shall have performed or complied with, in all material respects, all of its obligations required to be performed or complied with at or prior to the Closing Date; (vi) the accuracy of the representations and warranties, and the performance of the covenants and agreements, of the Company, Merger Sub and Vesicor, respectively, subject to customary materiality qualifications; (vii) the absence of a material adverse effect with respect to Vesicor; (viii) the Company?s initial listing application with the Nasdaq Stock Market, LLC, NYSE American or another agreed-upon national securities exchange (the ? Stock Exchange ?) in connection with the Merger has been conditionally approved and, immediately following the Effective Time, the Company has satisfied any applicable initial and continuing listing requirements of the Stock Exchange, and the New Vesicor Common Stock has been approved for listing on the Stock Exchange; (x) the execution of the Registration Rights Agreement and the Lock-Up Agreement; (xi) the Company?s satisfactory completion of its due diligence investigation of Vesicor; (xii) both parties? delivery of disclosure schedules within 30 days of the execution date of the Agreement; and (xiii) the parties obtaining sufficient financing prior to the Closing to pay transaction expenses and meet Altitude?s other obligations and the effectiveness of the registration statement on Form S-4 to be filed with the U.S. Securities and Exchange Commission. The Vesicor Therapeutics Board of Directors has unanimously (i) approved and declared advisable this Agreement and the transactions contemplated by this Agreement. Altitude Acquisition Board of Directors (including any required committee or subgroup of such board) has, (i) declared the advisability of the transactions contemplated by this Agreement.